Skip to main content

Advertisement

Log in

The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments

  • Original paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Within the series of articles investigating the burden of rheumatoid arthritis (RA), this paper reviews the methods used for economic assessment of the RA treatments by HTA agencies and other bodies involved in cost-effectiveness analysis and the current status of the field. The overall methods, as well as the challenges, of cost-effectiveness analysis in RA are common to all chronic progressive diseases where much of the treatment benefit is delayed, while costs occur immediately. Also, as in all disabling diseases, much of the costs occur outside the health-care system, due to the rapid loss of work capacity and the need for informal care in the later stages of the disease. Thus, it is essential to adopt a long-term view and consider costs from the perspective of society, rather than the health-care service, to increase the relevance of the results for policy making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Scott, D., Pugner, K., Kaarela, K., et al.: The links between joint damage and disability in rheumatoid arthritis. Rheumatology 39, 122–132 (2000)

    Article  Google Scholar 

  2. Pincus, T., Sokka, T., Wolfe, F.: Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 44, 1234–1236 (2001)

    Article  Google Scholar 

  3. Riise, T., Jacobsen, B., Gran, J., et al.: Total mortalilty is increased in rheumatoid arthritis. A 17 year prospective study. Clin. Rheumatol. 20, 123–127 (2001)

    Article  Google Scholar 

  4. Yelin, E., Turpin, L., Wong, B., Rush, S.: The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J. Rheumatol. 29, 1851–1857 (2002)

    Google Scholar 

  5. Chehata, J., Hassell, A., Clarke, S., et al.: Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology 40, 447–452 (2001)

    Article  Google Scholar 

  6. Jönsson B.: Quality of life and health economics. Where is the link? Scand. J. Gastroenterol. 31(Suppl 221), 33–36 (1996)

    Article  Google Scholar 

  7. Choi, H.K., Seeger, J.D., Kuntz, K.M.: A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J. Rheumatol. 29, 1156–1165 (2002)

    Google Scholar 

  8. Maetzel, A., Tugwell, P., Boers, M., group obotOER.: Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a reference case. J. Rheumatol. 30, 891–896 (2003)

    Google Scholar 

  9. Ware, J., Sherbourne, C., McHorney, C.: The MOS 36-Item Short Form Health Survey. Med. Care 31, 247–263 (1993)

    Article  Google Scholar 

  10. DeJong, Z., van der Heijde, D., McKenna, S., Whalley, D.: The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br. J. Rheumatol. 36, 878–883 (1997)

    Article  Google Scholar 

  11. Torrance, G.: Measurement of health state utilities for economic appraisal. A review. J. Health Econ. 5, 1–30 (1986)

    Article  Google Scholar 

  12. Drummond, M., O'Brien, B., Stoddart, G., Torrance, G.: Methods for the economic evaluation of health care. Kluwer, Boston (1997)

    Google Scholar 

  13. Kobelt, G.: Health economics: introduction to economic evaluation. Office of Health Economics, London (1996)

    Google Scholar 

  14. EuroQol: Group EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16, 199–208 (1990)

    Article  Google Scholar 

  15. Dolan, P., Gudex, C., Kind, P., Williams, A.: A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics, University of York, York. Report No.: Discussion paper 138 (1995)

  16. Torrance, G.: Measurement of health state utilities for economic appraisal. A review. J. Health Econ. 5, 1–30 (1986)

    Article  Google Scholar 

  17. Brazier, J., Roberts, J., Deverill, M.: The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21, 271–292 (2002)

    Article  Google Scholar 

  18. Wolfe, F., Mitchell, D., Sibley, J. et al.: The mortality of rheumatoid arthritis. Arthritis Rheum. 37, 481–494 (1994)

    Article  Google Scholar 

  19. Symmons, D., Jones, M., Scott, D., Prior P.: Long-term mortality outcome in patients with rheumatoid arthrits: early presenters continue to do well. J. Rheumatol. 25, 1072–1077 (1998)

    Google Scholar 

  20. Wallberg-Jonsson, S., Ohlman, M., Dahlqvist S.: Cardiovascular morbidity and mortality in patients with seroposivie rheumatoid arthritis in Northern Sweden. J. Rheumatol. 24, 445–451 (1997)

    Google Scholar 

  21. Jacobsson, L.T., Turesson, C., Gulfe, A., et al.: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213–1218 (2005)

    Google Scholar 

  22. Jacobsson, L.T., Turesson, C., Nilsson, J.A., et al.: Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 670–675 (2007)

    Article  Google Scholar 

  23. Kobelt, G.: Health economic issues in rheumatoid arthritis. Scand. J. Rheumatol. 35, 415–425 (2006)

    Article  Google Scholar 

  24. Kobelt, G., Eberhardt, K., Jönsson, L., Jönsson, B.: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 42, 347–356 (1999)

    Article  Google Scholar 

  25. Kobelt, G., Jönsson, L., Lindgren, P., et al.: Modelling the Progression of rheumatoid arthritis. A two-country model to estimate costs and consequences of RA. Arthritis Rheum. 46, 2310–2319 (2002)

    Article  Google Scholar 

  26. Guillemin, F., Briancon, S., Pourel, J.: Functional disability in rheumatoid arthritis: two different models in early and established disease. J. Rheumatol. 26, 800–804 (1992)

    Google Scholar 

  27. Aletaha, D., Smolen, J., Ward, M.M.: Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum. 54, 2784–2792 (2006)

    Article  Google Scholar 

  28. Fries, J., Spitz, P., Kraines, R., Holman, H.: Measurement of patient outcome in arthritis. Arthritis Rheum. 23, 137–145 (1980)

    Article  Google Scholar 

  29. Kobelt, G., Lindgren, P., Lindroth, Y., et al.: Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 44, 1169–1175 (2005)

    Article  Google Scholar 

  30. Hulsemann, J.L., Ruof, J., Zeidler, H., Mittendorf, T.: Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol. Int. 26, 704–711 (2005)

    Article  Google Scholar 

  31. Lajas, C., Abasolo, L., Bellajdel, B., et al.: Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 49, 64–70 (2003)

    Article  Google Scholar 

  32. Kobelt, G., Richard, B., Peeters, P., Sany, J.: Costs and quality of life of patients with RA in France. ACR abstract, Bone, Joint, Spine (in press) (2006)

  33. Marra, C.A., Woolcott, J.C., Kopec, J.A., et al.: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60, 1571–1582 (2005)

    Article  Google Scholar 

  34. Marra C.A., Marion S.A., Guh D.P., et al.: Not all "quality-adjusted life years" are equal. J. Clin. Epidemiol. 60, 616–624 (2007)

    Article  Google Scholar 

  35. Thompson, M., Leighton-Read, J., Hutchings, C., et al.: The cost effectiveness of auranofin. Results of a randomized clinical trial. J. Rheumatol. 15, 35–42 (1988)

    Google Scholar 

  36. Drummond, M.F., Barbieri, M., Wong, J.B.: Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference? Med. Decis. Making 25, 520–533 (2005)

    Article  Google Scholar 

  37. Bansback, N.J., Regier, D.A., Ara, R., et al.: An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 65, 473–496 (2005)

    Article  Google Scholar 

  38. Smolen, K., Kalden, J., Scott, D., et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized multicentre trial. Lancet 353, 259–266 (1999)

    Article  Google Scholar 

  39. Emery, P., Breedveld, F., Lemmel, E., et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39, 655–665 (2000)

    Article  Google Scholar 

  40. Strand, V., Tugwell, P., Bombardier, C., et al.: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum. 42, 1870–1878 (1999)

    Article  Google Scholar 

  41. Kobelt, G., Lindgren, P., Young, A., Eberhardt, K.: Cost and effects of leflunomide in the UK. Eur. J. Health Econ. 3, 173–179 (2002)

    Article  Google Scholar 

  42. Maini, R., Group tAS.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354, 1932–1939 (1999)

    Article  Google Scholar 

  43. Kobelt, G., Jönsson, L., Young, A., Eberhardt, K.: The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 42, 326–335 (2003)

    Article  Google Scholar 

  44. Weinblatt, M., Kremer, J., Bankhurst, A., et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253–312 (1999)

    Article  Google Scholar 

  45. Jobanputra, P., Barton, P., Bryan, S., et al.: The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. University of Birmingham, Birmingham (2004)

    Google Scholar 

  46. Barton, P., Jobanputra, P., Wilson, J., et al.: The use of modelling to evaluate new drugs for patients with chronic conditions: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol. Assess. 8, 1–91 (2004)

    Google Scholar 

  47. Kobelt, G., Eberhardt, K., Geborek, P.: TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann. Rheum. Dis. 63, 4–10 (2004)

    Article  Google Scholar 

  48. Wong, J., Singh, G., Kavanough, A.: Estimating the cost-effectiveness of infliximab for rheumatoid arthritis. Am. J. Med. 113, 400–408 (2002)

    Article  Google Scholar 

  49. Moreland, L., Schiff, M., Baumgartner, S., et al.: Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. 130, 478–486 (1999)

    Google Scholar 

  50. Brennan, A., Bansback, N., Nixon, R., et al.: Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) (2007)

  51. Bansback, N.J., Brennan, A., Ghatnekar, O.: Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann. Rheum. Dis. 64, 995–1002 (2005)

    Article  Google Scholar 

  52. Klareskog, L., van der Heijde, D., de Jager, J.P., et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004)

    Article  Google Scholar 

  53. Kobelt, G., Lindgren, P., Singh, A., Klareskog, L.: Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann. Rheum. Dis. 64, 1174–1179 (2005)

    Article  Google Scholar 

  54. Wolfe, F., Michaud, K., Pincus, T.: Do rheumatology cost-effectiveness analyses make sense?. Rheumatology 43, 4–6 (2004)

    Article  Google Scholar 

  55. Brennan, A., Bansback, N., Reynolds, A., Conway, P.: Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43, 62–72 (2004)

    Article  Google Scholar 

  56. Zink, A., Strangfeld, A., Schneider, M., et al.: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 54, 3399–3407 (2006)

    Article  Google Scholar 

  57. Wong, J., Ramey, D., Singh, G.: Long-term morbidity, mortality and economics of rheumatoid arthritis. Arthritis Rheum. 44, 2746–2749 (2001)

    Article  Google Scholar 

  58. Kobelt, G., Jönsson, L., Lindqvist, E., Eberhardt, K.: Cost-effectiveness of infliximab in Sweden. ACR San Francisco. Arthritis Rheum. (Abstract 2282) (2001)

  59. Barbieri, M., Wong, J.B., Drummond, M.: The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics 23, 607–618 (2005)

    Article  Google Scholar 

  60. Smolen, J., Breedveld, T., Burmester, G., et al.: Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann. Rheum. Dis. 59, 504–505 (2000)

    Article  Google Scholar 

Download references

Conflict of interest

This study has been funded by unrestricted grant from F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G. Kobelt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kobelt, G., Jönsson, B. The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ 8 (Suppl 2), 95–106 (2008). https://doi.org/10.1007/s10198-007-0091-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-007-0091-0

Keywords

JEL Classification

Navigation